Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne (NASDAQ: TECH) will host a conference call and webcast on Wednesday, May 6, 2026 at 8:00 a.m. CDT to review third quarter fiscal 2026 financial results.
Access details include U.S. and international dial-in numbers, conference ID TECHQ3, and a live webcast at the company investor site. A recorded replay will run from 11:00 a.m. CDT May 6 until 11:00 p.m. CDT June 6, 2026.
Bio-Techne (NASDAQ: TECH) on March 25, 2026 expanded its COMET spatial biology portfolio with new SPYRE Focus Panels (Stroma and Vessel) and SPYRE Amplification Kits. These add modular panel options, seqLA amplification for low-abundance targets, and HORIZON image-analysis enhancements to streamline hyperplex tissue workflows.
The release emphasizes increased sensitivity, faster setup, and flexibility for integrating lab antibodies across the COMET automated ecosystem to support research and preclinical studies.
Bio-Techne (NASDAQ: TECH) will present at two investor conferences in early March 2026: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 AM EST and Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:40 AM EDT. A live webcast will be available via the company's IR Calendar page.
Bio-Techne (NASDAQ: TECH) announced on Feb 16, 2026 that its Ella benchtop immunoassay platform received CE‑IVD marking and is now available for sale in the European Union. The cartridge-based system delivers biomarker results in under 90 minutes with minimal hands-on time.
The CE‑IVD mark supports Ella's use in clinical trials, in-house test development, and validated clinical applications, while Simple Plex assays remain indicated for research use only.
Bio-Techne (NASDAQ: TECH) announced leadership changes effective March 1, 2026. Dr. Matt McManus will transition from his role as President, Diagnostics and Spatial Biology Segment and will remain with the company temporarily to support a smooth transition. Steve Crouse is appointed President, Diagnostics and Spatial Biology Segment.
Steve Crouse joins from Bio-Techne's Analytical Solutions Division, brings over 20 years of industry experience, and is credited with launching platforms and delivering strong growth during his four-year tenure at Bio-Techne.
Management said McManus played a key role in organizational optimization, including the strategic divestiture of the Exosome business.
Bio-Techne (NASDAQ: TECH) announced a quarterly cash dividend of $0.08 per share for the quarter ended December 31, 2025. The dividend is payable February 27, 2026 to shareholders of record on February 16, 2026. Future dividends will be reviewed quarterly by the board.
The company reported over $1.2 billion in net sales for fiscal 2025 and has approximately 3,100 employees worldwide. The release includes standard forward-looking cautionary language about risks and uncertainties.
Bio-Techne (NASDAQ: TECH) reported second quarter fiscal 2026 revenue of $295.9 million, essentially flat year-over-year, with GAAP EPS of $0.24 and adjusted EPS of $0.46. Adjusted operating margin was 31.1%, up 100 basis points versus prior year, while GAAP operating income rose 15% to $54.5 million.
Management cited productivity initiatives and the Exosome Diagnostics divestiture as drivers of margin improvement, with continued strength in large pharma and growth in China/APAC. A conference call and replay are available February 4, 2026.
Bio-Techne (NASDAQ: TECH) launched Cultrex Synthetic Hydrogel on February 2, 2026, a fully defined synthetic extracellular matrix (ECM) for 3D stem cell and organoid culture. The product aims to reduce lot-to-lot variability, support scalable workflows, and align organoid research with regulatory and translational initiatives.
The hydrogel is presented as a synthetic alternative to animal-component matrices to improve reproducibility, traceability, and adoption of new approach methodologies (NAMs) in drug screening, toxicology, and personalized medicine.
Bio-Techne (NASDAQ: TECH) launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform on January 28, 2026, enabling femtogram-level detection of neurological biomarkers including NFL, GFAP, pTau 217, and Amyloid β (aa1-42).
The assays deliver improved analytical sensitivity, automated microfluidic workflow with under three-hour runtime, and build on Ella's extensive publication record to support earlier detection and reproducible quantification in neuroscience research. Assays are for Research Use Only.
Bio-Techne (NASDAQ: TECH) will host a conference call and webcast on Wednesday, February 4, 2026 at 8:00 a.m. CST to review second quarter fiscal 2026 financial results.
Live access: dial 1-800-579-2543 or 1-785-424-1789 (international) using Conference ID TECHQ2, or join the webcast at https://investors.bio-techne.com/ir-calendar. A recorded rebroadcast will be available from 11:00 a.m. CST on Feb 4, 2026 through 11:00 p.m. CST on Mar 4, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 and referencing Conference ID 11160826.